Last reviewed · How we verify
Bevacizumab (Bevacizumab-Bvzr)
Bevacizumab binds VEGF and prevents interaction with endothelial cell receptors Flt-1 and KDR.
ZIRABEV (bevacizumab-bvzr) is a VEGF-binding monoclonal antibody indicated for multiple solid tumors including metastatic colorectal cancer, non-squamous NSCLC, recurrent glioblastoma, metastatic renal cell carcinoma, cervical cancer, and epithelial ovarian cancer. The drug demonstrates linear pharmacokinetics with a 20-day half-life and steady-state achievement in approximately 84 days. No absolute contraindications exist, though clearance varies by body weight, sex, and tumor burden without evidence of reduced efficacy in males or high tumor burden patients. Bevacizumab shows minimal clinically meaningful drug interactions with common chemotherapy agents, though paclitaxel exposure may be reduced in some patients when combined with bevacizumab and carboplatin.
At a glance
| Generic name | Bevacizumab-Bvzr |
|---|---|
| Sponsor | Roche |
| Drug class | Monoclonal antibody |
| Target | Vascular Endothelial Growth Factor (VEGF) |
| Modality | Monoclonal antibody |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 2004 |
Mechanism of action
Bevacizumab products bind to VEGF and prevent the interaction of VEGF with its receptors (Flt-1 and KDR) on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial cell proliferation and new blood vessel formation in in vitro models of angiogenesis. Administration of bevacizumab to xenotransplant models of colon cancer in nude (athymic) mice caused reduction of microvascular growth and inhibition of metastatic disease progression.
Approved indications
- Carcinoma of cervix
- Glioblastoma multiforme
- Liver cell carcinoma
- Malignant epithelial tumor of ovary
- Malignant neoplasm of breast
- Malignant neoplasm of colon and/or rectum
- Malignant tumor of fallopian tube
- Malignant tumor of peritoneum
- Metastatic carcinoma to colon
- Metastatic renal cell carcinoma
- Non-small cell lung cancer with mutation in epidermal growth factor receptor
- Nonsquamous nonsmall cell neoplasm of lung
- Secondary malignant neoplasm of colon
Common side effects
- Fatigue
- Nausea
- Constipation
- Vomiting
- Hypertension
- Diarrhoea
- Diarrhea
- Anaemia
- Neutrophils
- Leukocytes
- Hemoglobin
- Cough
Drug interactions
- Irinotecan and active metabolite SN38
- Interferon alfa
- Carboplatin
- Paclitaxel
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bevacizumab CI brief — competitive landscape report
- Bevacizumab updates RSS · CI watch RSS
- Roche portfolio CI